Last mentioned: Mar 19, 2026
Pitt Breakthrough
Researchers reveal a new approach to bypass leptin resistance at the molecular level.
GLP-1 Dominance
Drugs like Wegovy and Zepbound revolutionize the obesity market.
Clinical Failures
Early leptin trials fail due to the discovery of leptin resistance in obesity.
Discovery of Leptin
Jeffrey Friedman identifies the hormone as a key regulator of body weight.
University of Pittsburgh researchers have identified a new mechanism to overcome leptin resistance, a major hurdle in obesity treatment. This approach aims to restore the brain's sensitivity to satiety signals, potentially offering a sustainable alternative to current GLP-1 therapies.
This page surfaces every story mentioning GLP-1 Agonists across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where GLP-1 Agonists was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |